About NCVC About NCVC About NCVC TOP The Center's Mission Organization History of the NCVC Location News Releases Close Hospital Hospital Hospital TOP About the Hospital The Group of Treatment Close Research Institute Research Institute Research Institute TOP About the Research Institute Departments Office for the Promotion of Diversity and Inclusion Research Institute and Open Innovation Center Brochure Close Open Innovation Center Open Innovation Center Open Innovation Center TOP Research Institute and Open Innovation Center Brochure Close Pamphlet National Cerebral and CardiovascularCenter Hospital Res. Inst. OICOpen Innovation Center Access Background White Black Japanese Access Menu National Cerebral and Cardiovascular Center TOP Research Institute Departments Department of Vascular Physiology Research Institute Department of Vascular Physiology  MemberDirectorYoshikazu NakaokaLaboratory ChiefMakoto OkazawaMasaki MoriStaff ScientistAtsushi NakanoTomohiko IshibashiTadakatsu InagakiPostdoctoral FellowSaori MizushimaRyotaro AsanoXin DingShuichi TonomuraYui KotaniAkiko YamagishiYuko Taira Kaori HigashiResearch AssistantNoriko MaederaToru NakajimaMika EjiriKokone HataNao ArakiData ManagerYuko Iwai Masayo Kusumoto  ResearchAim of our research group is to understand the molecular mechanisms and to develop novel therapeutic strategies for intractable cardiovascular diseases.We have been interested in the molecular pathogenesis of intractable vascular diseases such as pulmonary arterial hypertension (PAH) and Takayasu arteritis (TAK), especially focusing on inflammatory cytokines. In PAH animal models, we have found that both IL-6 and IL-21 have crucial roles in the pathogenesis of PAH. In addition, we recently reported that a transcriptional factor aryl hydrocarbon receptor (AHR) plays a critical role in the pathogenesis of PAH. On the other hand, we have been examining the efficacy of IL-6 blockade in patients with TAK. Through clinical trials, we could get the approval of tocilizumab, an IL-6 receptor monoclonal antibody, for treatment of TAK from the Japanese government.We are currently interested in the origin of inflammation of various cardiovascular diseases. We have been investigating the role of gut microbiome in the pathogenesis of cardiovascular diseases including PAH, TAK, stroke, heart failure and so on. We would like to develop novel therapeutic and diagnostic strategies for cardiovascular diseases through elucidating the molecular linkages between gut microbiome and inflammation. Publication Manabe Y, Ishibashi T, Asano R, Tonomura S, Maeda Y, Motooka D, Ueda J, Yanagawa M, Edamoto-Taira Y, Chikaishi-Kirino T, Masaki T, Inagaki T, Nakamura S, Katada Y, Okazawa M, Narazaki M, Ogo T, Kumanogoh A, Nakaoka Y*. Gut Dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis. Arthritis Res Ther. 2023. 25(1); 46; doi:10.1186/s13075-023-03031-9.Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y*, Takeuchi O*. Regnase-1 prevents pulmonary arterial hypertension via mRNA degradation of Interleukin-6 and Platelet-Derived Growth Factor in alveolar macrophages. Circulation.2022 Sep 27;146(13):1006-1022 (*equal contribution, *co-correspondence)Nakaoka Y, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 2021 Sep 16: keab684. doi: 10.1093/rheumatology/keab684.Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, Yamagishi A, Mizushima S, Nishimura M, Manabe Y, Ishibashi-Ueda H, Shirai M, Tsuchimochi H, Pearson JT, Kumanogoh A, Sakata Y, Ogo T, Kishimoto T, Nakaoka Y. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 118(11): e2023899118, 2021Inagaki T, Pearson JT, Tsuchimochi H, Schwenke DO, Saito S, Higuchi T, Masaki T, Umetani K, Shirai M, Nakaoka Y. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography. Am J Physiol Heart Circ Physiol. 2021 Mar 1; 320(3):H1021-H1036.Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434.Mori H, Ishibashi T, Inagaki T, Okazawa M, Masaki T, Asano R, Manabe Y, Ohta-Ogo K, Narazaki M, Ishibashi-Ueda H, Kumanogoh A, Nakaoka Y. Pristane/Hypoxia Mouse as a Novel Model of Pulmonary Hypertensin Reflecting Inflammation and Fibrosis. Circ J. 2020 Jun 25;84(7):1163-1172.last updated : 2024/03/15 (Corporate number:3120905003033) 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan TEL：81-6-6170-1070 Access Copyright © National Cerebral and Cardiovascular Center All rights reserved. Site setting Font-size Normal Large Background White Black Japanese English